Article
Biochemistry & Molecular Biology
Jozsef Kiraly, Erzsebet Szabo, Petra Fodor, Zsolt Fejes, Bela Nagy Jr, Eva Juhasz, Anna Vass, Mahua Choudhury, Gabor Konya, Gabor Halmos, Zsuzsanna Szabo
Summary: Shikonin induces apoptosis of renal cancer cells by activating the Ras/MAPK and PI3K/AKT pathways, suggesting its potential therapeutic implications for the treatment of renal cancer.
Article
Biochemistry & Molecular Biology
Anna Staskiewicz, Erica Wong, Michael Tucker, Riya Farhin, Jonathan Park, Rana Saade, Tina Alkhazali, Tu Dang, Xinyu Wang
Summary: Multiple myeloma (MM) is a cancer characterized by bone lesions, hypercalcemia, anemia, and renal failure. Bortezomib (BTZ) is a common treatment for MM, but can be toxic at high doses. Resveratrol (RES), a compound found in grapes, inhibits MM cell growth. This study identified a synergistic combination of BTZ and a RES derivative that decreased MM cell viability by inducing apoptosis and oxidative stress.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Analytical
Qingtong Wang, Ke Li, Huizhong Chi, Yang Fan, Boyan Li, Rongrong Zhao, Qindong Guo, Yanhua Qi, Wenhan Wang, Yanpeng Shi, Hong Liu, Aimin Song, Hao Xue, Gang Li, Yifei Zhang
Summary: Due to its invasiveness and heterogeneity, glioma exhibits different sensitivities to the same treatment, which are typically measured by the proliferative and apoptotic cell activities. This study reports a label-free method using terahertz metamaterials to simultaneously detect the proliferative and apoptotic features of glioma cells. The biosensor consists of metamaterial resonators, whose frequency shifts as the cell number and state change. This work provides a new way to study the proliferative and apoptotic responses of tumor cells, showing potential for fast and label-free individualized tumor treatments.
SENSORS AND ACTUATORS B-CHEMICAL
(2023)
Article
Medicine, Research & Experimental
Qingqing Chen, Hongwei Han, Faxiang Lin, Liangjie Yang, Lu Feng, Xiaohui Lai, Zhongling Wen, Minkai Yang, Changyi Wang, Yudi Ma, Tongming Yin, Guihua Lu, Hongyan Lin, Jinliang Qi, Yonghua Yang
Summary: This study evaluated the anti-tumor activities of semi-synthesized shikonin (SK) derivatives against human breast cancer cells. The findings showed that these derivatives exhibited strong inhibition of cell proliferation and migration, and induced cell apoptosis through regulating apoptosis and glucose metabolism pathways.
Article
Oncology
Haleema Ahmad, Megan S. Crotts, Jena C. Jacobs, Robert W. Baer, James L. Cox
Summary: The study found that shikonin treatment can mainly induce necroptosis in B16F10 melanoma cells through pathways such as necroptosis, autophagy, and reactive oxygen species. Additionally, shikonin treatment can inhibit cell proliferation and increase the levels of stress-related proteins.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Caio C. D. Moncao, Carlos A. Scrideli, Augusto F. Andrade, Mariano S. Viapiano, Carlos G. Carlotti, Daniel Antunes Moreno, Mirella Baroni, Luiz G. Tone, Silvia A. Teixeira
Summary: Pediatric high-grade glioma (pHGG) is a highly aggressive brain tumor. This study evaluated the effects of the drug Indisulam on pHGG cell lines. The results showed that Indisulam significantly reduced cell proliferation, clonogenic capacity, and promoted apoptosis. It also affected the expression of apoptotic proteins, suggesting a potential to overcome chemotherapy resistance.
Article
Oncology
Yung-Lung Chang, Chung-Hsing Chou, Yao-Feng Li, Li-Chun Huang, Ying Kao, Dueng-Yuan Hueng, Chia-Kuang Tsai
Summary: This study examined the effects of three angiotensin II receptor blockers (ARBs) on the proliferation of glioblastoma multiforme (GBM) cell lines. Telmisartan was found to significantly suppress cell proliferation, migration, and invasion in these GBM cell lines. It also induced cell cycle arrest and apoptosis and targeted the SOX9 pathway. Additionally, telmisartan inhibited tumor growth in an animal model. These findings suggest that telmisartan could potentially be used as a treatment for GBM in humans.
CANCER CELL INTERNATIONAL
(2023)
Article
Cell & Tissue Engineering
Lei Yuan, Ting Zhang, Hong Pan, Fei Wang
Summary: The study demonstrated that Shikonin inhibits the Notch2 signaling pathway in U87 cells, promoting the degradation of Notch2 protein and reducing cell proliferation, which is associated with its antioxidant effect.
JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
(2021)
Article
Biochemistry & Molecular Biology
Zhiwei Weng, Hangjie Fu, Zhiguang Huang, Wenxia Li, Yixin Xie, Jianchang Yuan, Bin Ding
Summary: Shikonin (SHK) has been proven to be beneficial for psoriasis by inhibiting ferroptosis through reducing inflammation, improving oxidative stress, and iron accumulation. The study suggests that Nrf2 and GPX4 may be the two main targets of SHK in psoriatic skin lesions.
CHEMICO-BIOLOGICAL INTERACTIONS
(2023)
Article
Biochemistry & Molecular Biology
Paula Aldaz, Amaya Fernandez-Celis, Natalia Lopez-Andres, Imanol Arozarena
Summary: Dexamethasone (DEXA) is commonly used in glioblastoma (GBM) patients to reduce brain inflammation, activating the glucocorticoid receptor (GR) which can influence the mineralocorticoid receptor (MR) signaling. MR signaling in GBM has been shown to have anti-proliferative effects and inhibit the self-renewal of GSCs, while spironolactone (SPI) may not have significant anti-neoplastic potential in GBM.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Paul Humbert, Meadhbh A. Brennan, Julien De Lima, Regis Brion, Annie Adrait, Celine Charrier, Benedicte Brulin, Valerie Trichet, Yohann Coute, Frederic Blanchard, Pierre Layrolle
Summary: Osteoclasts play a key role in bone regeneration, and apoptosis is found to be important for the effectiveness of MSCs. Experimental results show that apoptotic secretion of MSCs can inhibit the development of inflammatory multinucleated giant cells.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Emilie Logie, Claudina Perez Novo, Amber Driesen, Pieter Van Vlierberghe, Wim Vanden Berghe
Summary: Protein kinases play a crucial role in transducing cellular signals and orchestrating biological processes through phosphorylation of substrate proteins. Recent studies have shown their involvement in ferroptosis, an iron-dependent cell death linked to toxic lipid peroxidation. Different kinase signaling changes are induced by apoptotic and ferroptotic cell death, indicating that kinome profiling could be a valuable approach to identify sensitization modalities of novel anti-cancer agents.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Wenxia Li, Hangjie Fu, Liuyuan Fang, Hui Chai, Tianwen Gao, Zhenzhen Chen, Shenxian Qian
Summary: Shikonin (SHK) can inhibit the development of multiple myeloma (MM) by inducing ferroptosis and immunogenic cell death (ICD). The ferroptotic effect of SHK on MM is mediated through ferritinophagy regulated by GOT1.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Kantapich Srikham, Mongkol Thirabunyanon
Summary: The potential and modes of action of novel human colostrum probiotics were investigated for their application in the prevention and treatment of colon cancer. Eight probiotic bacteria were identified that successfully inhibited the proliferation of colon cancer cells. The mode of action involved adhesion to colon cancer cells and induction of apoptotic cell death. These probiotics also stimulated the immune system.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Immunology
Chen Lyu, Birgit Stadlbauer, Lili Wang, Alexander Buchner, Heike Pohla
Summary: The management of ccRCC has changed rapidly with the introduction of ICIs, but many patients develop resistance to therapy. This study identifies shikonin as a promising combination partner with ipilimumab for the treatment of ccRCC, showing strong inhibitory effects on CSCs and activation of CD8+ and CD4+ T cells. Additionally, VCAM1 is identified as a potential immunotherapeutic target and novel CSC marker for ccRCC.
FRONTIERS IN IMMUNOLOGY
(2023)